CCL26-targeted siRNA treatment of alveolar type II cells decreases expression of CCR3-binding chemokines and reduces eosinophil migration: implications in asthma therapy.
Errahali YJ, Taka E, Abonyo BO, Heiman AS. CCL26-targeted siRNA treatment of alveolar type II cells decreases expression of CCR3-binding chemokines and reduces eosinophil migration: implications in asthma therapy. J Interferon Cytokine Res. 2009 Apr; 29(4):227-39.